Manufacturing method of L-cysteic acid

A biotechnological method using OAS sulfhydrylase and sulfite converts O-acetyl-L-serine into L-cysteic acid, addressing the sustainability and yield issues of existing methods, providing a viable industrial production process.

JP2024544367AActive Publication Date: 2024-11-29WACKER CHEMIE AG
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
JP2024531637
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2021-11-29
Publication Date
2024-11-29
Estimated Expiration
2041-11-29

AI Technical Summary

Technical Problem

Existing methods for producing L-cysteic acid are not sustainable and environmentally friendly, and they are not suitable for industrial use due to the use of harmful chemicals and low yields.

Method used

A biotechnological method using O-acetyl-L-serine sulfhydrylase (OAS sulfhydrylase) in the presence of sulfite to convert O-acetyl-L-serine (OAS) into L-cysteic acid, avoiding the use of harmful chemicals and achieving high yields.

Benefits of technology

This method produces L-cysteic acid in a sustainable and environmentally friendly manner, with high yields and without the need for extreme conditions or special equipment, making it suitable for industrial applications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024544367000001
    Figure 2024544367000001
  • Figure 2024544367000002
    Figure 2024544367000002
  • Figure 2024544367000003
    Figure 2024544367000003
Patent Text Reader

Abstract

The present invention relates to a method for producing L-cysteic acid, in which O-acetyl-L-serine (OAS) is reacted with at least one enzyme selected from the class of O-acetyl-L-serine sulfhydrylases (OAS sulfhydrylases, EC 4.2.99.8) in the presence of sulfite. This economical method for preparing L-cysteic acid is environmentally friendly, sustainable and technically easy to implement. Another advantage of this method is that it allows the preparation of natural L-cysteic acid, which is increasingly in demand.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a method for the production of L-cysteic acid, in which O-acetyl-L-serine (OAS) is converted using at least one enzyme selected from the class of O-acetyl-L-serine sulfhydrylases (OAS sulfhydrylases, EC 4.2.99.8) in the presence of sulfite, and L-cysteic acid is the result of this biotransformation. [Background technology]

[0002] L-cysteic acid can be used, for example, in fish farming (Nakamura et al., Fisheries Science (2021) 87:353-363) or in the cosmetics field (US4053630), for example as a component of Regu(R)-Slim (DSM) for skin care. In peptide chemistry, L-cysteic acid is used as a water-soluble protecting group. Furthermore, L-cysteic acid can be converted to taurine by decarboxylation.

[0003] L-cysteic acid ((R)-2-amino-3-sulfopropanoic acid, 3-sulfo-L-alanine, CAS 498-40-8) can be produced chemically, for example, by oxidation of cysteine ​​with chlorine in alcoholic solution (Tao et al., Amino Acids (2004), 27:149-151), by bromine in HCl or iodine HCl in DMSO, or by oxidative cleavage of cystine with performic acid. Furthermore, L-cysteic acid can also be produced by oxidation of L-cysteine ​​sulfinic acid. Known methods for chemical production of L-cysteic acid use chemicals that are not considered sustainable and are harmful to the environment, and are poorly accepted by consumers, especially for applications in the food, cosmetic and pharmaceutical fields. Therefore, there is a need for more environmentally friendly and more sustainable production methods, one option of which is biotechnological methods.

[0004] L-Cysteic acid is a non-proteinogenic L-amino acid that can be found in nature, e.g., in sheep's wool, as an oxidation product of the proteinogenic amino acid L-cysteine. Cysteic acid is also an intermediate in the biosynthesis of coenzyme M (CoM, 2-mercaptoethanesulfonic acid, CAS 3375-50-6) by methanogenic archaea.

[0005] The prior art provides methods for producing non-proteinogenic amino acids, for example by direct fermentation of microorganisms with deregulated cysteine ​​metabolism (EP1191106B1) or by OAS sulfhydrylase-catalyzed biotransformation of OAS (EP1247869B1). These methods are based on the OAS sulfhydrylase catalyzing the reaction of OAS with nucleophiles to form non-proteinogenic amino acids according to the general formula (1):

[0006] (1) OAS + nucleophile -> non-proteinogenic amino acid + acetate In cysteine ​​metabolism in Escherichia coli and other organisms, OAS serves as the biosynthetic precursor of L-cysteine. The latter is formed by replacing an acetate group at the beta position with a thiol group. This reaction, called beta-substitution, is catalyzed by enzymes of the OAS sulfhydrylase class (EC 4.2.99.8). Thus, OAS is the actual substrate (also called reactant) of the OAS sulfhydrylase reaction, and the nucleophile is the variable co-substrate.

[0007] In EP1247869B1, a number of different nucleophiles, including selenides, selenols, azides, cyanides, azoles and isoxazolinones, were tested for their suitability as nucleophiles for OAS sulfhydrylase-catalyzed (e.g., CysM-catalyzed) reactions with OAS. In addition, sulfur compounds from the group of thiosulfates and thiols of general formula HSR were tested, where the group R is a monovalent substituted or unsubstituted alkyl, alkoxy, aryl or heteroaryl group.

[0008] The produced amino acids are non-proteinogenic, such as S-phenyl-L-cysteine, which are not used in nature as building blocks for protein biosynthesis. None of the disclosed nucleophiles allows for the production of L-cysteic acid.

[0009] Joo et al. (2018), J.Agric.Food Chem. 66:13454-13463, describes a metabolic engineering approach for taurine production in the bacterium Corynebacterium glutamicum. To reach the production of taurine, the genes for L-cysteine ​​synthase, cysteine ​​dioxygenase and L-cysteine ​​sulfinic acid decarboxylase were heterologously expressed in this strain. In Figure 2 of Joo et al. (2018), J.Agric.Food Chem. 66:13454-13463, various metabolic pathways to taurine are described, including also a pathway starting from O-phospho-L-serine and leading to taurine via L-cysteic acid (the "L-cysteine ​​sulfonate pathway"), which in principle is also suitable for the production of L-cysteic acid. However, the diagram also shows that there is no known biosynthetic pathway from OAS to L-cysteic acid, only L-cysteine.

[0010] Tevatia et al., Algal Research (2015) 9:21-26, describes the natural production of taurine in microalgae, where L-cysteic acid has also been detected as an intermediate. As described in Tevatia et al., Algal Research (2015) 9:21-26, Fig. 1a), the biosynthetic pathway leads from L-serine to L-cysteic acid ("cystate" in Fig. 1a). None of the described biosynthetic pathways leads to L-cysteic acid via OAS. Microalgal growth is not suitable for the production of L-cysteic acid, since the intracellular content of L-cysteic acid detected in microalgae was very low and was accompanied by multiple by-products that make post-processing more difficult, such as methionine, cysteine, cysteine ​​sulfinic acid, hypotaurine and taurine.

[0011] In the metabolic engineering approach, US2019 / 0062757A1 (KnipBio) describes a heterologous production strain for taurine production, which is intended to be suitable for the production of L-cysteic acid as well. In figures 4-9 and 12 of US2019 / 0062757A1, various biosynthetic pathways to taurine containing L-cysteic acid as an intermediate are described, and thus in principle suitable for the production of L-cysteic acid. None of these biosynthetic pathways start from OAS. Furthermore, only yields of hypotaurine and taurine were reported, which were very low, up to 419 ng / ml. No yields for the production of L-cysteic acid are mentioned. It must be assumed that for L-cysteic acid, higher yields cannot be achieved. This metabolic engineering approach is therefore not suitable for the biotechnological production of L-cysteic acid.

[0012] Ono et al. (Free Radical Biology and Medicine 106, 69-79, 2017) disclose that the OAS sulfhydrylases CysM and CysK from Salmonella entericum LT2 can form cysteine ​​from the substrates OAS and sulfide in high yields of over 70%, similar to the enzyme from E. coli (Maier, Nature Biotechnology 21, 422-427, 2003, see Table 1). Ono further shows that CysM and CysK from Salmonella entericum LT2 can form cysteine ​​from Na 2 SO 3 Others disclose that in the presence of OAS, the cysteine ​​derivative L-cysteic acid (cysteine ​​sulfonate, cysteate) can be further formed from OAS under identical reaction conditions in low amounts, i.e., less than 0.2% molar yield.

[0013] Therefore, the prior art discloses only chemical methods and does not disclose an economically viable biotechnological method for producing L-cysteic acid suitable for industrial use. [Prior art documents] [Patent documents]

[0014] [Patent Document 1] U.S. Pat. No. 4,053,630 [Patent Document 2] European Patent No. 1191106 [Patent Document 3] European Patent No. 1247869 [Patent Document 4] US Patent Application Publication No. 2019 / 0062757 [Non-patent literature]

[0015] [Non-Patent Document 1] Nakamura et al.,Fisheries Science(2021)87:353-363 [Non-Patent Document 2] Tao et al. Amino Acids (2004)27:149-151 [Non-Patent Document 3] Joo et al.(2018),J.Agric.Food Chem.66:13454-13463 [Non-Patent Document 4] Tevatia et al.,Algal Research(2015)9:21-26 [Non-Patent Document 5] Ono et al., Free Radical Biology and Medicine (2017) 106, 69-79 [Non-Patent Document 6] Maier, Nature Biotechnology (2003) 21, 422-427 Summary of the Invention

[0016] The object of the present invention is to provide a biotechnological method for the production of L-cysteic acid by biotransformation. [Means for solving the problem]

[0017] This object is achieved by a method for producing L-cysteic acid, in which O-acetyl-L-serine (OAS) is converted in the presence of sulfite using at least one enzyme selected from the class of O-acetyl-L-serine sulfhydrylases (OAS sulfhydrylases, EC 4.2.99.8), which provides L-cysteic acid produced by biotransformation.

[0018] The advantage of the method according to the invention is that it is a sustainable and technically feasible biotransformation method for producing L-cysteic acid. Environmentally harmful chemicals can be dispensed with. No fossil raw materials are consumed and no toxic chemical waste and / or waste gases are produced. The production method of the invention is therefore environmentally friendly and sustainable. Furthermore, the method is technically easy to implement since it does not require either extreme reaction conditions or special equipment. Another advantage of the method is that natural L-cysteic acid, which is increasingly in demand, can be produced in this way.

[0019] Surprisingly, sulfite (hereafter referred to as sulfite or SO3 2- It has now been found that the nucleophile (referred to as "Cysteamine") is suitable as a nucleophile in reaction (1) and allows the synthesis of L-cysteic acid in a previously unknown reaction according to formula (2).

[0020] (2) OAS+SO3 2- -> L-Cysteic acid + acetate DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0021] In the context of the present invention a distinction is made between the following manufacturing processes:

[0022] 1.Chemical method 2. Biotechnological methods: a) Metabolic engineering Metabolic engineering (also called "pathway design"), in contrast to biotransformation, is a biotechnological method in which metabolic pathways of organisms are modified by optimizing or modifying genes and regulatory processes. New or modified enzymes can be introduced into an organism by supplementing the genome with the genes of the enzymes, or genes of endogenous enzymes can be expressed at enhanced or attenuated levels, thereby establishing new metabolic pathways in the organism or enhancing or attenuating existing metabolic pathways. The goal of metabolic engineering is for an organism to produce either new metabolites or cell-endogenous metabolites in high yields. Metabolic engineering methods do not use starting materials specific for metabolites, such as enzyme substrates, e.g. OAS in the present invention. Instead, they only use nutrient media, also called growth media, that are necessary for the growth of the organism in question and are composed of a carbon source (e.g. glucose), a nitrogen source (e.g. ammonium salts or complex amino acid mixtures such as peptones or yeast extracts) and other salts necessary for growth. Such nutrient media are known to the skilled artisan from microbiological practice.

[0023] b) Biotransformation Biotransformation is defined as the conversion of one or more reactants to products under enzyme catalysis, where the enzyme substrate is added to the reaction batch together with the enzyme. In the reaction batch, the added enzyme substrate, for example the OAS of the invention, is enzymatically converted according to formula (2) (in the present invention by an enzyme selected from the class of OAS sulfhydrylases (EC 4.2.99.8) in the presence of sulfite). The reactants can originate from chemical or biotechnological production. The OAS used in the process according to the invention can be obtained, for example, from chemical synthesis or from biotechnological production by fermentation of a production strain. The enzymes used for the enzyme catalysis originate from biotechnological production by growth of a production strain, for example by fermentation, or biological material containing the enzymes is used (for example from plants, fungi, algae, animal organs). Biomass or biological material from the growth of a production strain can be used directly or the enzyme is isolated therefrom depending on the requirements of the biotransformation. The CysM enzyme used in the process according to the invention originates from biotechnological production by fermentation of a production strain.

[0024] A natural production method is defined as a biotechnological production method that does not use genetically modified organisms (GMOs) or products (reactants, enzymes) from production using GMOs. In the present invention, the method for producing L-cysteic acid is a natural production method when OAS and OAS sulfhydrylase as organic reactants are not produced using GMOs and are not produced chemically. Sulfite as co-substrate in formula (2) is an inorganic compound and is essentially a product of dissolving SO2 in water according to formulas (4)-(8), which does not correspond to a (irreversible) chemical synthesis, but to the reversible hydration of gas SO2 and the pH-dependent dissociation of the hydrate H2SO3.

[0025] Autocloning within the meaning of § 3 sentence 3, paragraph 4 of the Gentechnikgesetz (GenTG, German Genetic Engineering Act) is, according to the statement issued by the Zentrale Kommission fur biologische Sicherheit (ZKBS, German Central Committee for Biological Safety) (reference: 6790-10-02 of 1991), a method in which only one species, genetically identical or different in form, including its viruses and plasmids, is used as donor and recipient organism.

[0026] In the context of the present invention, a reaction batch is defined as a mixture of reactants (starting materials), enzyme and optionally other reactants, which are converted into products.

[0027] The yield of a reaction in the sense of the present invention is defined as the amount of reactant used that is converted into product under reaction conditions. The yield can be expressed as an absolute amount (g or mmol), as a volumetric yield (concentration) as an absolute amount of product per unit volume (mM or g / L), or as a relative yield of product as a percentage of the reactants used (taking into account the molecular weights of the reactants and products), also called the yield percentage.

[0028] Fermentation is a method step for the production (cultivation) of cell cultures on an industrial scale, in which preferably microbial production strains are grown under defined conditions of culture medium, temperature, pH, oxygen supply and mixing of the medium. Depending on the constitution (genetic constitution) of the production strain, the aim of the fermentation is to produce proteins / enzymes or metabolic products, in each case in the highest possible yield for further use. The components of the process according to the invention, OAS and OAS sulfhydrylase, can be produced by fermentation. The end product of fermentation is the fermenter broth, consisting of the biomass of cells of the production strain (fermenter cells) and the fermentation medium (fermentation supernatant) removed from the biomass and formed from the growth medium and metabolic products secreted by the fermenter cells during fermentation. The target product of the fermentation can be present in the fermenter cells or in the fermentation medium. For example, OAS is found in the fermentation medium and the enzyme OAS sulfhydrylase is found in the fermenter cells.

[0029] Open reading frame (ORF, synonymous with cds or coding sequence) refers to a region of DNA or RNA that begins with a start codon, ends with a stop codon, and codes for the amino acid sequence of a protein. ORFs are also called coding regions or structural genes.

[0030] A gene refers to a segment of DNA that contains all the basic information to produce biologically active RNA. A gene includes a segment of DNA that is transcribed to produce a single-stranded RNA copy, and expression signals involved in regulating this copying process. Expression signals include, for example, at least one promoter, transcription initiation, translation initiation, and a ribosome binding site (RBS). Terminators and one or more operators are additional possible expression signals.

[0031] A genetic construct refers to a DNA molecule in which a gene is linked to other genetic elements (e.g., promoters, terminators, selection markers, origins of replication). A genetic construct in the context of the present invention is a circular DNA molecule, called a plasmid, vector or expression vector. The genetic elements of the genetic construct cause its extrachromosomal inheritance during cell growth and cause the production of the protein encoded by the gene.

[0032] The L-cysteic acid from the biotransformation of OAS by sulfite according to the invention can be used directly further without further post-treatment steps or can be concentrated or purified by known methods, where the degree of concentration depends on the further use. Such methods are known to those skilled in the art from methods for isolating amino acids. Examples include filtration, centrifugation, extraction, adsorption, ion exchange chromatography, precipitation, crystallization.

[0033] In a preferred embodiment, the method comprises concentrating L-cysteic acid from the reaction batch. Removal of particulate biomass, for example by centrifugation, is particularly preferred.

[0034] In a further preferred embodiment, the process provides that the L-cysteic acid produced by the process according to the invention is further used directly, i.e. the reaction batch containing L-cysteic acid is further used without further work-up, purification or isolation steps, including filtration, centrifugation, extraction, adsorption, ion exchange chromatography, precipitation and crystallization.

[0035] OAS sulfhydrylases have been isolated from a wide variety of plants and microorganisms. In E. coli, for example, there are two OAS sulfhydrylase enzymes called CysK and CysM. The related genes are also known and are called cysK and cysM, respectively.

[0036] OAS sulfhydrylases within the meaning of the present invention are capable of catalyzing the synthesis of the proteinogenic amino acid L-cysteine ​​from OAS according to formula (3), where the nucleophile used is a sulfide. Thus, both CysM-related and CysK-related enzymes are OAS sulfhydrylases within the meaning of the present invention.

[0037] (3) OAS+S 2- ->L-cysteine ​​+ acetate Although both enzymes have very similar reaction mechanisms and are involved in the biosynthesis of L-cysteine, CysM, unlike CysK, has a variable substrate spectrum with respect to the nucleophiles that can react with OAS according to equation (1).

[0038] For example, it is known that CysM, unlike CysK, can catalyze the reaction of OAS with thiosulfate to form S-sulfocysteine ​​(CAS number 1637-71-4), a reaction that plays an important role in bacterial growth with thiosulfate as the sole sulfur source.

[0039] Furthermore, EP1247869B1 (Wacker) discloses the use of CysM for the production of non-proteinogenic amino acids.

[0040] Preferably, this method is characterized in that the OAS sulfhydrylase is a bacterial enzyme, particularly preferably CysM, especially preferably CysM from an E. coli strain.

[0041] Sulfurous acid forms a number of species that exist simultaneously in reversible equilibrium, and the suitability of each of them as a nucleophile in the biotransformation according to the present invention was not predictable. Thus, it is known that sulfurous acid (H2SO3) is an aqueous solution of gaseous SO2, and as a dibasic acid, it exists in different equilibrium states depending on the pH of the aqueous solution, and the suitability of the species in this equilibrium state also changes as a nucleophile. The following equilibrium theories (4) to (8) are known.

[0042] (4) SO2 (gaseous) <-> SO2 (dissolved) (5)SO2(dissolved)+H2O<->H2SO3 (6) H2SO3<->HSO3 - +H + (7) HSO3 - <->SO3 2- +H + (8) 2HSO3 - <->S2O5 2- +H2O Sulfurous acid and its salts are used as preservatives in the food industry because they exhibit antibacterial effects. This means that sulfurous acid and its salts can kill microorganisms, which is due to the inactivation of enzymes necessary for the survival of microorganisms. Therefore, a person skilled in the art would expect that when using sulfurous acid or its salts, CysM enzyme will also be inactivated, and L-cysteic acid cannot be prepared by the method disclosed in EP1247869B1.

[0043] For the reasons stated above, it was surprising to those skilled in the art that sulfite and OAS could be used in the biotransformation to produce L-cysteic acid.

[0044] In principle, all possible sulfites are suitable for the reaction.Preferably, in this method, the sulfite salt used is Na2SO3, K2SO3, (NH4)2SO3, NaHSO3 (or its anhydride Na2S2O5) or KHSO3.Particularly preferably, the sulfite salt used is Na2SO3, NaHSO3 (or its anhydride Na2S2O5) and (NH4)2SO3, particularly preferably Na2SO3 and NaHSO3 (or its anhydride Na2S2O5).

[0045] It is possible to use gaseous sulfur dioxide, anhydride of sulfurous acid, which can be introduced into the reaction batch and is hydrated to sulfurous acid H2SO3 and, depending on the pH, the deprotonated form HSO3 - and SO3 2- is in equilibrium with

[0046] This method requires the availability of OAS. For example, chemical methods for producing OAS by acetylation of L-serine are expensive due to the high price of L-serine, or the production of racemic O-acetyl-D / L-serine, which can be used directly, or OAS can be obtained in advance from the racemate, for example, by resolution. In the case of direct acetylation, N-acetyl-L-serine (NAS) can be formed as a by-product, for example, by non-selective acetylation of the hydroxyl or amino groups of L-serine, or by the known rearrangement of OAS to NAS at neutral to alkaline pH values ​​(Tai et al. (1995), Biochemistry 34:12311-12322), which reduces the yield or requires the prior introduction of a protecting group at the amino group of L-serine. Therefore, direct acetylation of L-serine is not practical for an economically viable method.

[0047] Biotechnological production of OAS is also known, as disclosed for example in EP1233067B1. This involves the use of organisms that exhibit a deregulated cysteine ​​metabolism and thus provide high levels of OAS. As a result, cost-effective production systems for producing OAS are available.

[0048] In a preferred embodiment, the method comprises enriching the OAS from a fermentation production, which can be carried out using GMO or non-GMO organisms.

[0049] In a particularly preferred embodiment, the method is characterized in that the OAS is produced fermentatively with the aid of a non-GMO microorganism, whereby it is particularly preferred that the OAS is produced fermentatively with the aid of the E. coli strain W3110 / pACYC-cysEX-GAPDH-ORF306. The last-mentioned specifically preferred embodiment is disclosed in Example 1.

[0050] The method for producing L-cysteic acid according to the present invention is preferably a natural production method, which means that not only are there no GMOs used in the method, but both the reactant OAS and the enzyme OAS sulfhydrylase are derived from natural production, i.e., they are not produced using GMOs and are not chemically produced.

[0051] This particularly preferred embodiment is disclosed in the examples according to the invention, which describe a method for the natural production of L-cysteic acid, in which both OAS and OAS sulfhydrylase CysM are naturally produced. Both the OAS producing strain E. coli strain W3110 / pACYC-cysEX-GAPDH-ORF306 (example 1) and the CysM producing strain E. coli DH5α / pFL145 (example 2) are derived from autocloning and are not classified as GMOs. The fact that both OAS and OAS sulfhydrylase can be produced without the use of GMOs provides a particular advantage to the invention, since the invention discloses a method for the natural production of L-cysteic acid, which is of great interest due to its possible applications in the supply sector and cosmetics.

[0052] One skilled in the art can use isotopic analysis to determine whether a substance desired to be used as a reactant in the present method, such as OAS, is derived from chemical or fermentative production. A distinguishable isotopic analysis method is described, for example, in Sieper et al., Rapid Commun. Mass Spectrom (2006) 20:2521-2527, and is based on determining the isotope ratios, for example of carbon or nitrogen, which vary depending on whether the product is derived from chemical (petroleum-based) or fermentative production (derived from plant-based feedstock).

[0053] An advantage of the present invention is that OAS-containing fermenter broth, such as that obtained from a fermentation carried out according to EP 1 233 067 B1, can be used directly in the method according to the invention as a source of OAS after removal of the particulate biomass, for example by centrifugation without further work-up, purification or isolation steps, including extraction, adsorption, ion exchange chromatography, precipitation and crystallization. This procedure is particularly economical and avoids the isolation of unstable compounds.

[0054] A fermentation method for producing OAS, using the E. coli strain W3110 / pACYC-cysEX-GAPDH-ORF306, is disclosed in EP1233067B1 and in Example 1 of the present invention. This strain has been deposited according to the Budapest Treaty at the DSMZ (German Collection of Microorganisms and Cell Cultures GmbH, Braunschweig) under the number DSM 13495.

[0055] The method preferably provides that the OAS sulfhydrylase (preferably comprising CysM) is derived from a fermentative production, particularly preferably produced fermentatively with the aid of a non-GMO microorganism, particularly preferably produced with the aid of an E. coli strain including the aid of the E. coli DH5α / pFL145 strain.

[0056] Example 2 discloses a procedure for the fermentative biotechnological production of CysM using the strain E. coli DH5α / pFL145. The production strain consists of a host strain, in this case E. coli DH5α, and a genetic construct suitable for the expression of OAS sulfhydrylase, preferably the genetic construct pFL145. The host strain and the genetic construct as well as the creation of the production strain are described in EP1247869B1 (Wacker). This production strain has been deposited under the number DSM 14088 at the DSMZ-German Collection of Microorganisms and Cell Cultures GmbH (Braunschweig) according to the Budapest Treaty.

[0057] In the method according to the invention, the OAS sulfhydrylase obtained by fermentation can be used as fermenter broth without further workup or as a cell suspension after reisolation of the cells from the fermenter broth, for example by centrifugation.Furthermore, the OAS sulfhydrylase can be used in the form of a cell homogenate after mechanical disruption of the cell suspension, or in the form of chemically permeabilized cells (for example with chloroform), or as a cell extract after removal of particulate components from the cell homogenate, or as an enzyme purified, for example by chromatography.

[0058] The use of OAS sulfhydrylase as fermenter broth without further workup, as a cell suspension after reisolation of the cells from the fermenter broth, or as a cell homogenate after mechanical disruption of the cell suspension, or in the form of chemically permeabilized cells (e.g., with chloroform) is preferred.

[0059] Particularly preferred is the use of OAS sulfhydrylase as a cell suspension or cell homogenate following reisolation of the cells from the fermenter broth.

[0060] In a particularly preferred embodiment, cells of the production strain isolated and resuspended from the fermenter broth are used as the OAS sulfhydrylase.

[0061] In a particularly preferred embodiment, the method for producing L-cysteic acid is one in which both the OAS sulfhydrylase and the OAS are produced by fermentation.

[0062] OAS as reactant in the biotransformation process according to the invention isomerizes from a pH of about pH 7 to N-acetyl-L-serine, which is then no longer suitable for reaction with sulfite, forming L-cysteic acid. The mechanism of the reaction was studied in Tai et al. (1995), Biochemistry 34:12311-12322, and involves an intramolecular nucleophilic attack by the deprotonated amino group on the carbonyl carbon of the acyl group. This reaction is inhibited when the pH is decreased, so that the compound is stable at, for example, pH 4.0.

[0063] The biotransformation method according to the invention is therefore distinguished by the fact that the reaction of OAS to form L-cysteic acid is carried out under pH conditions which minimize the isomerization of OAS to N-acetyl-L-serine.

[0064] Preferably, the process is carried out such that the reaction is carried out at a pH value of at least 5.5 and ≦7.5, particularly preferably ≦7.0, particularly preferably ≦6.5.

[0065] In a further preferred embodiment of the biotransformation method, the substrate OAS is metered into the reaction batch consisting of OAS sulfhydrylase and sulfite in a so-called feeding step (Example 5). The metered OAS is set at a pH that inhibits the isomerization to N-acetyl-L-serine, preferably at a pH ≦ 6.5, particularly preferably at a pH ≦ 6.0, particularly preferably at a pH ≦ 5.5. At the same time, the pH in the reaction batch is adjusted to promote the reaction to form L-cysteic acid.

[0066] According to equation (2), the reaction of OAS to form L-cysteic acid will release a stoichiometric amount of acetic acid, which may result in a decrease in pH in the batch as the reaction proceeds. Too low a pH will affect the activity of OAS sulfhydrylase, so an excessive decrease in pH must be prevented. This can be done passively by an appropriate high concentration buffer in the batch, or can be achieved actively by a measurement and control unit.

[0067] As disclosed in Example 5, active pH control by a measuring and control unit is preferred, which restores the desired pH by metered addition of alkaline solution or acid if the pH deviates from the target value (so-called pH-stat method).

[0068] The reaction temperature is preferably selected between 5 and 70° C. A reaction temperature of 10 to 60° C. is preferred, 15 to 50° C. is particularly preferred, and 20 to 40° C. is particularly preferred.

[0069] The process for producing L-cysteic acid is preferably carried out in an aqueous environment, i.e. the solvent used in the reaction is preferably water.

[0070] The method according to the invention for producing L-cysteic acid can be carried out in discontinuous or continuous operation. In discontinuous operation (batch operation), all reactants are added to the batch in the course of the reaction, and the batch is worked up after the reaction is finished. In continuous operation, OAS, OAS sulfhydrylase and sulfite are metered in continuously during the reaction, and the solution containing the product L-cysteic acid is removed from the batch at the same time. What is established is a steady state in which the reactants are metered in so that they can react completely during the residence time in the reaction vessel to form the product L-cysteic acid. Methods for the continuous production of unnatural amino acids are disclosed, for example, in EP1247869B1 (Wacker).

[0071] The discontinuous operation of the process according to the invention for producing L-cysteic acid is preferred.

[0072] Preferably, the method comprises a concentration of sulfite at least equimolar to OAS, particularly preferably at least a 1.5-fold molar excess, particularly preferably at least a 2-fold molar excess, and even more preferably at least a 5-fold molar excess.

[0073] The OAS concentration in the batch is preferably at least 1 g / L, particularly preferably at least 10 g / L, particularly preferably at least 40 g / L.

[0074] In the biotransformation of OAS, the molar yield of L-cysteic acid, based on the molar amount of OAS used, is preferably at least 60%, particularly preferably at least 70%, particularly preferably at least 80%.

[0075] The present invention is further illustrated by, but not limited to, the following examples. EXAMPLES

[0076] [ Example 1 ] Generation of OAS The E. coli strain W3110 / pACYC-cysEX-GAPDH-ORF306 was used, as disclosed in EP1233067B1 (Wacker) and deposited under number DSM 13495 at the DSMZ-German Collection of Microorganisms and Cell Cultures GmbH (Braunschweig) according to the Budapest Treaty. OAS was produced by fermentation as described in EP1233067B1. At the end of the fermentation, OAS was stabilized by setting the pH to 4.5 using 21% (v / v) phosphoric acid. Cells were removed by centrifugation (Heraeus Megafuge 1.0 R) at 4000 rpm for 10 min. The HPLC-determined content of OAS in the fermentation supernatant was 15.3 g / L.

[0077] HPLC analysis of OAS and L-cysteic acid: The quantification of the compounds analyzed in the examples used HPLC methods calibrated for OAS and L-cysteic acid, respectively. All reference substances used for calibration were commercially available (Sigma-Aldrich). For pre-column derivatization with o-phthaldialdehyde (OPA derivatization), as known from the analysis of amino acids, an Agilent 1260 Infinity II HPLC system was used, equipped with units from the same manufacturer. For detection of the OPA derivatization products OAS and L-cysteic acid, the HPLC system was equipped with a fluorescence detector. The detector was set at an excitation wavelength of 330 nm and an emission wavelength of 450 nm. A Thermo Scientific™ Accucore™ aQ column (length 100 mm, internal diameter 4.6 mm, particle size 2.6 μm) was also used, thermally equilibrated at 40° C. in the column oven.

[0078] Eluent A: 25 mM Na phosphate, pH 6.0. Eluent B: methanol. Separation was performed in gradient mode from 10% eluent B to 60% eluent B over 0-25 min, followed by 60% eluent B to 100% eluent B over 2 min, followed by 100% eluent B for another 2 min at a flow rate of 0.5 ml / min. Retention time of L-cysteic acid: 3.2 min. Retention time of OAS: 17.0 min.

[0079] [ Example 2 ] Production of the enzyme CysM We used the strain Escherichia coli (E. coli) DH5α / pFL145, disclosed in EP1247869B1 (Wacker) and deposited according to the Budapest Treaty at the DSMZ-German Collection of Microorganisms and Cell Cultures GmbH (Braunschweig) under number DSM 14088. The CysM enzyme was produced both by growth in shake flasks and by fermentation.

[0080] A) Growth in shake flasks: A preculture of E. coli strain DH5α / pFL145 was prepared in LBamp medium (10 g / l tryptone (GIBCO™), 5 g / l yeast extract (BD Biosciences), 5 g / l NaCl, 100 mg / L ampicillin (Sigma-Aldrich)) (grown overnight at 37° C. and 120 rpm). 25 ml of the preculture was used as inoculum for the main culture of 250 ml of LBamp medium (1 L Erlenmeyer flask with baffles). The main culture was shaken at 30° C. and 110 rpm. After 4 h, a cell density OD of 1.0 / ml was obtained. 600 reached (OD 600 : Photometric determination of cell density per ml of cell suspension by measuring absorbance at 600 nm; Genesys™ 10S UV-Vis spectrophotometer from Thermo Scientific™). The inducer tetracycline (Sigma-Aldrich, final concentration 3 mg / L) was then added and growth was continued for another 20 hours at 30° C. and 110 rpm. At the end of growth, the cell density OD 600 was 3 / ml.

[0081] B) Fermentative production of CysM using E. coli DH5α / pFL145 strain is disclosed in EP1247869B1. Cells from the fermentation were removed by centrifugation (Heraeus Megafuge 1.0 R) at 4000 rpm for 10 min and the cell density OD 600 The cells were suspended in KPi6.5 buffer (0.1 M K phosphate, pH 6.5) at a concentration of 90 / ml.

[0082] Cells from shake flask growth or fermentation were isolated by centrifugation (15000 rpm for 10 min, Sorvall RC5C centrifuge with SS34 rotor) for further use. The cell pellet was resuspended in KPi6.5 buffer as a cell suspension for further use for the production of cell homogenates, as described below. The cell suspension was determined by cell density OD 600 The OD of 3 / ml was prepared by using a sufficient amount of KPi6.5 buffer to obtain an OD of 30 / ml. 600 50 ml of cells from shake flask growth with 0.01% ethanol were centrifuged and resuspended in 5 ml of KPi6.5 buffer (10x concentration) or at an OD of 90 / ml. 600 1 ml of cells from the fermentation with was resuspended in 3 ml of KPi6.5 buffer (3-fold dilution).

[0083] This produced cells of the E. coli strain DH5α / pFL145 that were isolated from the fermenter broth and resuspended, which were used below as the OAS sulfhydrylase CysM in the method according to the invention.

[0084] To prepare the cell homogenate, a FastPrep-24™ 5G cell homogenizer from MP Biomedicals was used. A cell density OD of 30 / ml was used. 6001 ml of cell suspension in KPi6.5 buffer with was disrupted (3 x 20 sec at a shaking frequency of 6000 rpm with a 30 sec pause between each interval) in a 1.5 ml tube assembled by the manufacturer containing glass beads ("Lysis Matrix B"). The resulting cell homogenate was either used directly as OAS sulfhydrylase (CysM enzyme) in the method according to the invention or used for the preparation of cell extracts.

[0085] To prepare the cell extract, the resulting cell homogenate was centrifuged (15000 rpm for 10 min in a Sorvall RC5C centrifuge with a SS34 rotor) and the supernatant was called cell extract and was used as OAS sulfhydrylase (CysM enzyme) in the method according to the invention or was further used for the measurement of CysM enzyme activity.

[0086] The protein content of the cell extracts was determined by Qubit 3.0 Fluorometer from Thermo Fisher Scientific using the "Qubit® Protein Assay Kit" according to the manufacturer's instructions. The protein content of the cell extract from shake flask growth was 5.3 mg / ml. The protein content of the cell extract from fermentation was 4.0 mg / ml.

[0087] CysM enzyme activity was determined as described in EP1247869B1 (Wacker). For this purpose, OAS (Sigma-Aldrich) was incubated at 37°C in the presence of Na2S and cell extract from E. coli DH5α / pFL145 strain grown. Assays in KPi6.5 buffer (final volume 0.4 ml) contained 10 mM OAS (added from a 200 mM stock solution in 500 mM sodium succinate buffer pH 5.5), 10 mM sodium sulfide Na2S and 5 μl of CysM-containing cell extract. Cysteine ​​produced in the CysM reaction was measured with ninhydrin (Sigma-Aldrich) according to the method by Gaitonde (1967), Biochem. J. 104:627-633. The CysM enzyme activity in cell extracts from growth of E. coli DH5α / pFL145 strain in shake flasks was 57.1 U / ml. The cells from shake flask growth (OD 3 / ml) 600 ) was concentrated 10-fold for the preparation of cell extracts, so that the enzyme activity in cells from shake flask growth was 5.7 U / ml. CysM enzyme activity in cell extracts after fermentation of E. coli DH5α / pFL145 strain was 58.1 U / ml. Cells from fermentation (OD of 90 / ml) 600 ) at an OD of 30 / ml for the preparation of cell extracts. 600 The fermenter cells were diluted to OD 600 ) The enzyme activity in the cell suspension was 174.4 U / ml.

[0088] The specific CysM enzyme activity of cell extracts from E. coli DH5α / pFL145 strain grown in shake flasks was 10.8 U / mg protein. The specific CysM enzyme activity of cell extracts after fermentation of E. coli DH5α / pFL145 strain was 14.5 U / mg. Assuming that CysM activity was completely released from the cells during preparation of the cell extracts, the CysM enzyme activity measured in the cell extracts was comparable to the enzyme activity present in the CysM cell suspensions in the following examples.

[0089] 1 U / ml CysM enzyme activity is defined as 1 μmol / min cysteine ​​production from OAS and Na2S under assay conditions in 1 ml cell extract (volume activity). Specific CysM enzyme activity in U per mg protein is obtained by dividing the volume activity of the cell extract (U / ml) by the protein concentration of the cell extract (mg / ml) and is defined as the CysM enzyme activity in U based on mg of protein in the cell extract.

[0090] [ Example 3 ] Production of L-cysteic acid from commercial OAS and Na2SO3 using CysM produced in shake flask cultures Two batches were run in parallel: Batch 1: A 100 ml Erlenmeyer flask was initially charged with 8.25 ml of NaPi6.5 buffer (50 mM Na phosphate, pH 6.5) and successively added 1 ml of a 0.2 M solution of Na2SO3 in NaPi6.5 buffer, 0.4 ml of CysM cell extract from shake flask growth (from Example 2A) with an activity of 57.1 U / ml (final concentration in batch 2.3 U / ml), and 350 μl of a 0.2 M solution of OAS×HCl (Sigma-Aldrich) in 0.5 M Na succinate, pH 5.5. The batch volume was 10 ml.

[0091] Batch 2: Batch (comparison batch without Na2SO3) had the same composition as batch 1. Instead of Na2SO3 solution, batch 2 received 1 ml of NaPi6.5 buffer.

[0092] Both batches were incubated at 37° C. and 140 rpm in a chest shaker (Infors). After 1 and 3 hours, 1 ml of each batch was incubated at 80° C. for 5 min to stop the reaction, centrifuged and the supernatants were analyzed by HPLC. The amount of L-cysteic acid detected by HPLC is shown in Table 1.

[0093] Table 1: HPLC-detected amount of L-cysteic acid as a function of reaction time using commercial OAS and Na2SO3 and CysM-containing cell extracts.

[0094] [Table 1]

[0095] [ Example 4 ] Production of L-cysteic acid from OAS-containing culture supernatant and Na2SO3 from fermentation using CysM produced in shake flask cultures A 100 ml Erlenmeyer flask was initially charged with 1 ml of cell culture supernatant from the fermentation of E. coli strain W3110 / pACYC-cysEX-GAPDH-ORF306 with an OAS content of 15.3 g / L (from Example 1), and supplemented with 6 ml of NaPi6.5 buffer, 1 ml of a 1 M solution of Na2SO3 in NaPi6.5 buffer, and 2 ml of CysM cell suspension from shake flask growth (cell density OD of 30 / ml, from Example 2A). 600 ; 57.1 U / ml CysM enzyme activity) was added successively. The batch volume was 10 ml. The CysM enzyme activity in the batch was 11.4 U / ml. The batch was incubated at 37° C. and 140 rpm in a chest shaker (Infors). After 2 hours, 1 ml batches were incubated at 80° C. for 5 min, centrifuged and the supernatants were analyzed by HPLC for OAS and L-cysteic acid content. The course of the reaction over time is summarized in Table 2.

[0096] Table 2: HPLC detection amounts of L-cysteic acid and OAS using OAS-containing cell culture supernatants, Na2SO3 and CysM-containing cell suspensions.

[0097] [Table 2]

[0098] [ Example 5 ] Preparation of L-cysteic acid by biotransformation of OAS at constant pH A 0.5 L thermostated double-walled glass vessel (Diehm) was connected via a hose connection to a thermostat (Lauda) and adjusted to a temperature of 37°C.

[0099] 50 ml of CysM-containing cell suspension in KPi6.5 buffer from fermentation of strain DH5α / pFL145 (from Example 2B) (OD of 90 / ml) 600 , CysM enzyme activity 8720 U) and 6.6 ml of a 400 g / L solution of Na2S2O5 (13.9 mmol, molecular weight 190.1 g / mol) in KPi6.5 buffer were initially charged. In dissolved form, this corresponded to 27.8 mmol of NaHSO3 (1.78-fold molar excess relative to the amount of OAS of 15.6 mmol to be weighed later). The batch was stirred with a magnetic stirrer. The batch was also equipped with a pH electrode (Mettler Toledo), which was connected to a pH control unit (TitroLine alpha titrator, Schott), which was operated in pH-stat mode according to the manufacturer's instructions. Under pH-stat conditions, the pH in the reaction vessel was kept constant at a set pH of 6.5 for the entire duration of the reaction by metered addition of 2 M NaOH from a burette connected to the control unit. 150 ml of OAS-containing cell culture supernatant (OAS content: 15.3 g / L, 2.3 g; 15.64 mmol) from the fermentation of E. coli strain W3110 / pACYC-cysEX-GAPDH-ORF306 (Example 1) was metered from a reservoir to the batch via a pump (Watson Marlow 101U / R peristaltic pump) at a flow rate of 0.35 ml / min.

[0100] The reaction time was 19 hours. Since the batch was carried out in an open reaction vessel, the batch volume was 185 ml after completion of the reaction by evaporation. At 0.5, 3 and 19 hours after the start of the reaction, 1 ml aliquots of the batch were removed and the L-cysteic acid content was analyzed by HPLC. The formation of L-cysteic acid over time is summarized in Table 3. After 19 hours of reaction time, the L-cysteic acid content in the batch was 12970 mg / L (76.65 mM), which corresponded to an absolute molar yield of 14.18 mmol of L-cysteic acid for a batch volume of 185 ml. Based on the amount of OAS used of 15.64 mmol, this corresponded to a yield of 90.1%.

[0101] Table 3: HPLC-detected amount of L-cysteic acid as a function of reaction time using OAS-containing fermentation supernatants, NaHSO3 and cell suspensions of fermenter cells containing CysM.

[0102] [Table 3]

Claims

1. A method for producing L-cysteic acid, comprising the steps of: A method, wherein O-acetyl-L-serine (OAS) is converted using at least one enzyme selected from the class of O-acetyl-L-serine sulfhydrylases (OAS sulfhydrylases, EC 4.2.99.8) in the presence of sulfite.

2. 2. The method of claim 1, wherein the OAS sulfhydrylase is a bacterial enzyme.

3. 3. The method of claim 1 or 2, wherein the OAS sulfhydrylase is CysM from an E. coli strain.

4. The method according to one or more of claims 1 to 3, wherein the OAS sulfhydrylase is derived from fermentative production.

5. The method according to one or more of claims 1 to 4, wherein the OAS sulfhydrylase is produced fermentatively with the aid of a non-GMO microorganism.

6. The method according to one or more of claims 1 to 5, wherein the OAS sulfhydrylase is produced fermentatively with the aid of the E. coli strain DH5α / pFL145.

7. The method according to one or more of claims 1 to 6, wherein the OAS is derived from a fermentative production.

8. The method according to one or more of claims 1 to 7, wherein the OAS is produced fermentatively with the aid of non-GMO microorganisms.

9. The method according to one or more of claims 1 to 8, wherein the OAS is produced fermentatively with the aid of the E. coli strain W3110 / pACYC-cysEX-GAPDH-ORF306.

10. The method according to one or more of claims 1 to 9, wherein the method is a naturally occurring method.

11. The sulfite used is Na 2 SO 3 , K 2 SO 3 , (NH 4 ) 2 SO 3 , or its anhydride Na 2 S 2 O 5 ) or KHSO 3 The method according to one or more of claims 1 to 10, wherein

12. 12. The method according to one or more of the preceding claims, wherein the concentration of sulfite is at least equimolar relative to the OAS.

13. The method according to one or more of the preceding claims, wherein the reaction is carried out at a pH of at least 5.5 and less than 7.

5.

14. 14. The method according to one or more of the preceding claims, wherein the molar yield of L-cysteic acid based on the molar amount of OAS used is at least 60%.

15. 15. The method according to one or more of the preceding claims, wherein L-cysteic acid is concentrated from the reaction batch.

Citation Information

Patent Citations

  • JP1973016193B1

  • Method for manufacturing non-protein l-amino acid

    JP2002315595A

  • Establishment of synthesis method for cysteine with isotopically labeled sulfur atom and cysteine derivative

    WO2017188355A1

  • Verfahren zur fermentativen Herstellung von nicht-proteinogenen L-Aminosäuren

    EP1191106A1

  • Process for the production of non-proteinogenic amino acids

    EP1247869A1